These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35085647)

  • 21. Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System.
    Coons JC; Iasella CJ; Chanas T; Wang N; Williams K; Boyd A; Lyons J; Eckardt J; Rihtarchik L; Merkel A; Chambers A; Lemon LS; Smith R; Ensor CR
    Ann Pharmacother; 2017 Aug; 51(8):649-655. PubMed ID: 28438043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM
    JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The paradox of clopidogrel use in patients with acute coronary syndromes and diabetes: insight from the Diabetes and Acute Coronary Syndrome Registry.
    Ferlini M; Musumeci G; Grieco N; Rossini R; De Servi S; Mafrici A; Sponzilli C; Demarchi A; Assanelli EM; Camisasca P; Chizzola G; Corrada E; Farina A; Pedrinazzi C; Lettieri C; Oltrona Visconti L
    Coron Artery Dis; 2018 Jun; 29(4):309-315. PubMed ID: 29309286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
    O'Donoghue ML; Murphy SA; Sabatine MS
    Circulation; 2020 Aug; 142(6):538-545. PubMed ID: 32551860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study.
    Alexopoulos D; Vogiatzi C; Stavrou K; Vlassopoulou N; Perperis A; Pentara I; Xanthopoulou I
    Cardiovasc Diabetol; 2015 May; 14():68. PubMed ID: 26025572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
    Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
    Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
    Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
    Abergel E; Nikolsky E
    Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
    Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Potent Oral P2Y
    Ma S; Li Z; Yu P; Song H; Jiang Z; Li Y; Han Y
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):199-208. PubMed ID: 32006144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
    Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
    EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry.
    De Luca L; D'Ascenzo F; Musumeci G; Saia F; Parodi G; Varbella F; Marchese A; De Servi S; Berti S; Bolognese L
    EuroIntervention; 2017 Jul; 13(4):459-466. PubMed ID: 28374678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expert Opinion on P2Y12 Inhibitors Use in Management of Acute Coronary Syndromes: Focus on Ticagrelor.
    Sathyamurthy I; Hiremath MS; Sawhney JP; Chandra S; Mishra H; Ponde CK; Ray S; Hardas S; Sathe S; Rath PC; R B; Navasundi GB; Magarkar V; Makhale CN; Banerjee S; Vaidyanathan PR; Sen AK; Bp P; C SO
    J Assoc Physicians India; 2021 Oct; 69(10):11-12. PubMed ID: 34781659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency and Reasons of Dual Antiplatelet Therapy Discontinuation and Switching of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome Treated with Stent Implantation.
    Fuertes Ferre G; Caballero Jambrina I; Ruiz Aranjuelo A; Jimeno Sánchez J; Galache Osuna JG; Andrés Esteban EM; Casasnovas Lenguas JA; Diarte de Miguel JA
    Cardiology; 2019; 142(4):203-207. PubMed ID: 31266007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.
    Paarup Dridi N; Johansson PI; Lønborg JT; Clemmensen P; Radu MD; Qayyum A; Pedersen F; Kollslid R; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2015; 26(6):521-9. PubMed ID: 25166751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of diabetic patients hospitalized for acute coronary syndromes: a prospective multicenter registry.
    Ferlini M; Musumeci G; Demarchi A; Grieco N; Mafrici A; De Servi S; Rossini R; Sponzilli C; Bognetti P; Cardile A; Frattini S; Ielasi A; Russo A; Vecchiato C; Lettieri C; Visconti LO
    J Cardiovasc Med (Hagerstown); 2017 Aug; 18(8):572-579. PubMed ID: 28590305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.
    Dayoub EJ; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Giri J; Groeneveld PW
    JAMA Intern Med; 2018 Jul; 178(7):943-950. PubMed ID: 29799992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: Systematic review and meta-analysis.
    Fujisaki T; Kuno T; Ando T; Briasoulis A; Takagi H; Bangalore S
    Am Heart J; 2021 Jul; 237():34-44. PubMed ID: 33737060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiplatelet therapy in acute coronary syndromes.
    Grove EL; Würtz M; Thomas MR; Kristensen SD
    Expert Opin Pharmacother; 2015; 16(14):2133-47. PubMed ID: 26293612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.